Literature DB >> 7994821

Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction.

E Loh1, J S Stamler, J M Hare, J Loscalzo, W S Colucci.   

Abstract

BACKGROUND: Pulmonary vascular resistance (PVR) is frequently elevated in patients with advanced heart failure. Nitric oxide (NO), which contributes to the activity of endothelium-derived relaxing factor, causes relaxation of pulmonary arteries and veins in vitro. Inhalation of NO gas causes pulmonary vasodilation in patients with primary and secondary forms of pulmonary hypertension. METHODS AND
RESULTS: To test the hypothesis that inhalation of NO gas lowers PVR in patients with heart failure, we studied the hemodynamic effects of a 10-minute inhalation of NO (80 ppm) in 19 patients with New York Heart Association class III (n = 5) and class IV (n = 14) heart failure due to left ventricular (LV) dysfunction. Although inhalation of NO had no effect on pulmonary artery pressures, the PVR decreased by 31 +/- 7% (P < .001) due to a 23 +/- 7% increase (P < .001) in pulmonary artery wedge pressure and despite a 4 +/- 2% (P < .05) decrease in cardiac index. The magnitude of the decrease in PVR with inhaled NO was inversely related (r = -.713; P < .001) to the baseline PVR. Inhaled NO had no effect on heart rate, systemic arterial pressure, systemic vascular resistance, or LV peak +dP/dt or -dP/dt.
CONCLUSIONS: In patients with heart failure due to LV dysfunction, inhalation of NO causes a decrease in the PVR associated with an increase in LV filling pressure. These findings predict that inhaled NO, if used alone at this dose (80 ppm), may have adverse effects in patients with LV failure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7994821     DOI: 10.1161/01.cir.90.6.2780

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

Review 1.  Right ventricular failure: a novel era of targeted therapy.

Authors:  Dipanjan Banerjee; Francois Haddad; Roham T Zamanian; Jayan Nagendran
Journal:  Curr Heart Fail Rep       Date:  2010-12

2.  S-nitrosothiol repletion by an inhaled gas regulates pulmonary function.

Authors:  M P Moya; A J Gow; T J McMahon; E J Toone; I M Cheifetz; R N Goldberg; J S Stamler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

3.  Early Left Ventricular Dysfunction and Severe Pulmonary Hypertension Predict Adverse Outcomes in "Low-Risk" Congenital Diaphragmatic Hernia.

Authors:  Duy T Dao; Neil Patel; Matthew T Harting; Kevin P Lally; Pamela A Lally; Terry L Buchmiller
Journal:  Pediatr Crit Care Med       Date:  2020-07       Impact factor: 3.624

4.  A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine.

Authors:  S Beloucif; D Payen
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

5.  The role of nitric oxide in heart failure. Potential for pharmacological intervention.

Authors:  P Macdonald; C Schyvens; D Winlaw
Journal:  Drugs Aging       Date:  1996-06       Impact factor: 3.923

Review 6.  Delivery and monitoring of inhaled nitric oxide.

Authors:  J D Young; O J Dyar
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

7.  Approach to patients with heart failure and pulmonary hypertension.

Authors:  Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

8.  Inhaled nitric oxide improves pulmonary hypertension and organ functions after adult heart valve surgeries.

Authors:  Takeichiro Nakane; Jiro Esaki; Ryoma Ueda; Masanori Honda; Hitoshi Okabayashi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2021-05-25

9.  Management of severe pulmonary hypertension in patients undergoing mitral valve surgery.

Authors:  Carlos D Davila; Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-06

10.  Nitric oxide and promotion of cardiac myocyte apoptosis.

Authors:  Péter Andréka; Thanh Tran; Keith A Webster; Nanette H Bishopric
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.